A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Small Bowel Crohn's Disease, sponsored by Gilead Sciences. Completed at 38 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-23.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 230th largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 141 in phase 2, and was the 334th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 37 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission defined as Crohn's disease activity index (CDAI) \< 150, at Week 24 in participants with small bowel Crohn's disease (CD). Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.
Key Inclusion Criteria:
Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines):
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
Drug: Filgotinib · Drug: Placebo to match filgotinib
Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
Drug: Filgotinib · Drug: Placebo to match filgotinib
PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
Drug: Placebo to match filgotinib
Tablet(s) administered orally once daily
Also known as: GS-6034, GLPG0634
Tablet(s) administered orally once daily
Percentage of Participants Who Achieved Clinical Remission at Week 24
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease (CD). The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.
Time frame: Week 24
Change From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24
Magnetic resonance enterography (MRE) is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and relative contrast enhancement (RCE). A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these components for the terminal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.
Time frame: Baseline; Week 24
Change From Baseline in Distal Ileum Segmental MaRIA Score at Week 24
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.
Time frame: Baseline; Week 24
Change From Baseline in Jejunum Segmental MaRIA Score at Week 24
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system.The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A positive change from baseline indicates disease worsening.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in terminal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
Time frame: Week 24
Percentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in distal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
Time frame: Week 24
Percentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in jejunum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
Time frame: Week 24
Percentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ minimum detectable difference (MDD) units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the terminal ileum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
Time frame: Week 24
Percentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score≥ 7 in the distal ileum. For segments with baseline MaRIA score ≥ 15, the minimum detectable difference (MDD) is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
Time frame: Week 24
Percentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the jejunum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
Time frame: Week 24
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Small bowel MaRIA remission was defined as MaRIA score \< 7 at Week 24 in each of the 3 small bowel segments, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.
Time frame: Week 24
Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 24
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Participant level small bowel MaRIA response was defined as all small bowel segments with baseline MaRIA score ≥7 achieve segment level MaRIA response, with no segment level disease worsening in any other segment(s) at Week 24, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.
Time frame: Week 24
Percentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.
Time frame: Week 10
Change From Baseline in CDAI Scores at Week 10
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement.
Time frame: Baseline; Week 10
Change From Baseline in CDAI Scores at Week 24
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement.
Time frame: Baseline; Week 24
Participants were enrolled at study sites in the United States, Canada, and Europe. The first participant was screened on 11 April 2017. The last study visit occurred on 20 July 2020.
| Milestone | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Started | 28 | 32 | 18 |
| Completed | 16 | 16 | 11 |
| Not completed | 12 | 16 | 7 |
| Withdrew: Non-responder at week 10 | 6 | 6 | 4 |
| Withdrew: Protocol-specified disease worsening | 3 | 3 | 1 |
| Withdrew: Adverse event | 1 | 5 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 0 | 0 |
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease (CD). The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 24 | 25.0 (12.4 to 41.9) | 25.0 (13.1 to 40.6) | 16.7 (4.7 to 37.7) |
Magnetic resonance enterography (MRE) is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and relative contrast enhancement (RCE). A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these components for the terminal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.
| score on scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Terminal Ileum Segmental Magnetic Resonance Index of Activity (MaRIA) Score at Week 24 | -1.8 ± 1.51 | 0.7 ± 1.39 | 0.5 ± 1.64 |
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system. The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement and a positive change from baseline indicates disease worsening.
| score on scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Distal Ileum Segmental MaRIA Score at Week 24 | -1.1 ± 1.12 | -0.5 ± 1.08 | 0.5 ± 1.26 |
MRE is an imaging technique to evaluate disease activity in CD. MaRIA is an MRE-based scoring system.The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at Screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer. Segmental scores less than 7 indicate remission in that segment. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A positive change from baseline indicates disease worsening.
| score on scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Jejunum Segmental MaRIA Score at Week 24 | 0.4 ± 1.00 | 0.6 ± 0.95 | 0.5 ± 1.12 |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in terminal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Remission in Terminal Ileum Segment at Week 24 | 4.5 (0.2 to 19.8) | 6.7 (1.2 to 19.5) | 6.3 (0.3 to 26.4) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in distal ileum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Remission in Distal Ileum Segment at Week 24 | 10.0 (0.5 to 39.4) | 0 (0.0 to 31.2) | 16.7 (0.9 to 58.2) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA remission was defined as a segmental MaRIA score \< 7 in jejunum segment at Week 24 among participants with MaRIA score ≥ 7 in the same segment at baseline. A segmental score of ≥ 7 indicates active inflammation and a score of ≥ 11 indicates the presence of an ulcer.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Remission in Jejunum Segment at Week 24 | 33.3 (6.3 to 72.9) | 0 (0.0 to 31.2) | 0 (0.0 to 63.2) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the terminal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ minimum detectable difference (MDD) units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the terminal ileum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Response in Terminal Ileum Segment at Week 24 | 22.7 (9.4 to 42.0) | 10.0 (2.8 to 23.9) | 25.0 (9.0 to 48.4) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the distal ileum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score≥ 7 in the distal ileum. For segments with baseline MaRIA score ≥ 15, the minimum detectable difference (MDD) is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Response in Distal Ileum Segment at Week 24 | 20.0 (3.7 to 50.7) | 12.5 (0.6 to 47.1) | 16.7 (0.9 to 58.2) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for the jejunum segment of the small bowel. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. MaRIA response was defined as a segmental MaRIA score \< 11 with baseline score ≥ 11, or a segmental MaRIA score \< 7 with baseline score \< 11, or ≥ MDD units decrease from baseline score for segments with baseline MaRIA score ≥ 7 in the jejunum. For segments with baseline MaRIA score ≥ 15, the MDD is 6.5 units and for baseline MaRIA score \< 15, the MDD is 4.0 units.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved MaRIA Response in Jejunum Segment at Week 24 | 50.0 (15.3 to 84.7) | 12.5 (0.6 to 47.1) | 0 (0.0 to 63.2) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Small bowel MaRIA remission was defined as MaRIA score \< 7 at Week 24 in each of the 3 small bowel segments, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Remission at Week 24 | 8.0 (1.4 to 23.1) | 6.3 (1.1 to 18.4) | 0 (0.0 to 15.3) |
The MaRIA scoring system is a composite index of 4 components. These components are edema, ulcers, gut wall thickness, and RCE. A segmental MaRIA score can be calculated at screening (used as the baseline) and Week 24 as a weighted sum of these 4 components for each of the 3 small bowel segments. The MaRIA score ranges from approximately 0 to 31, for any given segment. A higher score indicates more severe disease. Participant level small bowel MaRIA response was defined as all small bowel segments with baseline MaRIA score ≥7 achieve segment level MaRIA response, with no segment level disease worsening in any other segment(s) at Week 24, among participants with MaRIA score ≥ 7 in at least 1 small bowel segment at baseline.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Participant Level Small Bowel MaRIA Response at Week 24 | 20.0 (8.2 to 37.5) | 12.5 (4.4 to 26.4) | 16.7 (4.7 to 37.7) |
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. Clinical remission by CDAI was defined as a score of \< 150. A higher score indicates more severe disease.
| percentage of participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Early Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10 | 39.3 (23.8 to 56.5) | 25.0 (13.1 to 40.6) | 22.2 (8.0 to 43.9) |
The CDAI score is used to quantify the symptoms of participants with CD. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Difference in least squared means (Diff in LSM) were from analysis of covariance (ANCOVA) model. A negative change from baseline indicates improvement.
| score on scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Change From Baseline in CDAI Scores at Week 10 | -105 ± 23.6 | -88 ± 22.3 | -57 ± 26.2 |
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. The score ranges from 0 to 600. A score of \< 150 indicates remission. A higher score indicates more severe disease. Diff in LSM were from ANCOVA model. A negative change from baseline indicates improvement.
| score on scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Change From Baseline in CDAI Scores at Week 24 | -86 ± 24.1 | -71 ± 22.8 | -66 ± 26.7 |
Collected over All-Cause Mortality: First dose date up to last dose date (maximum: 28.7 weeks) plus 59 days; Adverse Events: First dose date up to last dose date (maximum: 28.7 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib 200 mg | 1/28 (3.6%) | 4/28 (14.3%) | 20/28 (71.4%) |
| Filgotinib 100 mg | 0/32 (0%) | 7/32 (21.9%) | 24/32 (75%) |
| Placebo | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 2/28 | 4/32 | 0/18 |
| Small intestinal obstructionGastrointestinal disorders | 2/28 | 0/32 | 0/18 |
| IleusGastrointestinal disorders | 0/28 | 1/32 | 0/18 |
| Anal abscessInfections and infestations | 0/28 | 1/32 | 0/18 |
| PneumoniaInfections and infestations | 0/28 | 1/32 | 0/18 |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 5/28 | 6/32 | 1/18 |
| Crohn's diseaseGastrointestinal disorders | 4/28 | 6/32 | 2/18 |
| NauseaGastrointestinal disorders | 5/28 | 3/32 | 1/18 |
| SinusitisInfections and infestations | 4/28 | 0/32 | 1/18 |
| HeadacheNervous system disorders | 4/28 | 4/32 | 2/18 |
| NasopharyngitisInfections and infestations | 0/28 | 4/32 | 0/18 |
| VomitingGastrointestinal disorders | 1/28 | 2/32 | 2/18 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/28 | 1/32 | 2/18 |
| DizzinessNervous system disorders | 1/28 | 2/32 | 2/18 |
| InfluenzaInfections and infestations | 3/28 | 1/32 | 0/18 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 46 ± 16.3 | 42 ± 12.9 | 45 ± 12.9 | 44 ± 14.2 |
| Sex: Female, Male(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 19 | 23 | 9 | 51 |
| Male | 9 | 9 | 9 | 27 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 0 | 0 | 0 | 0 |
| Race — Black or African American | 2 | 4 | 2 | 8 |
| Race — Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| Race — White | 25 | 28 | 16 | 69 |
| Race — Other | 1 | 0 | 0 | 1 |
| Race — Not Permitted | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 26 | 31 | 17 | 74 |
| Ethnicity — Hispanic or Latino | 2 | 1 | 1 | 4 |
| Ethnicity — Not Permitted | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 15 | 13 | 10 | 38 |
| Hungary | 0 | 3 | 1 | 4 |
| Czechia | 0 | 1 | 0 | 1 |
| Ukraine | 2 | 0 | 1 | 3 |
| United Kingdom | 4 | 1 | 2 | 7 |
| Spain | 1 | 2 | 0 | 3 |
| Canada | 0 | 4 | 1 | 5 |
| Austria | 1 | 1 | 0 | 2 |
| Belgium | 0 | 2 | 0 | 2 |
| Italy | 3 | 1 | 1 | 5 |
| France | 2 | 2 | 1 | 5 |
| Germany | 0 | 2 | 1 | 3 |
| Crohn's Disease Activity Index Score (CDAI)(score on scale) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 309 ± 55.7 | 297 ± 64.9 | 300 ± 63.7 | 302 ± 60.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Jul 2020, 39 months.
Results were first posted in Aug 2021, 1 year after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 39 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634